Company news

Share this article:

Neurogen is taking a charge of about $1.5 million in the first quarter of 2008 in connection with laying off 70 workers. The payments will cover severance benefits and other charges. According to Neurogen, the move is part of a restructuring to focus resources on advancing its pipeline of insomnia and other compounds including Phase II candidate aplindore for Parkinson's diseaseĀ and restless legs syndrome.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions